ストックスクリーナーアプリを入手
5.56
2.28%
-0.13
前日終値:
$5.69
開ける：
$5.6
24時間の取引高:
139.50K
Relative Volume:
0.59
時価総額：
$88.90M
収益：
$5.12M
当期純損益:
$-67.00M
株価収益率:
-3.7823
EPS:
-1.47
ネットキャッシュフロー:
$-38.94M
1週間 パフォーマンス:
-15.89%
1か月 パフォーマンス:
-30.67%
6か月 パフォーマンス:
-18.48%
1年 パフォーマンス:
-14.46%
1日の値動き範囲:
$5.41
$5.79
1週間の範囲:
$5.41
$7.15
52週間の値動き範囲:
$3.28
$9.8212
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
名前
Verrica Pharmaceuticals Inc
セクター
電話
484-453-3300
住所
10 NORTH HIGH STREET, WEST CHESTER, PA
Compare VRCA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
5.56 | 90.98M | 5.12M | -67.00M | -38.94M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-06 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | アップグレード | Needham | Hold → Buy |
| 2023-03-22 | 開始されました | Jefferies | Buy |
| 2023-02-13 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-12-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-06-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-24 | 開始されました | Northland Capital | Outperform |
| 2020-03-24 | 開始されました | Needham | Buy |
| 2019-02-21 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Verrica Pharmaceuticals Inc (VRCA) 最新ニュース
Verrica Pharmaceuticals appoints Chris Chapman as chief commercial officer - marketscreener.com
Verrica Pharmaceuticals (VRCA) Appoints New Chief Commercial Off - GuruFocus
Verrica Pharmaceuticals Inc. Appoints Chris Chapman as Chief Commercial Officer - Quiver Quantitative
VTAMA launch leader joins Verrica to drive YCANTH skin treatment - Stock Titan
Verrica’s Japanese Market Debut: A Strategic Expansion Unfolds - AD HOC NEWS
Verrica’s partner launches molluscum treatment in Japan By Investing.com - Investing.com South Africa
Verrica announces launch of Ycanth in Japan by Torii - The Pharma Letter
Verrica Pharmaceuticals stock rises after partner launches YCANTH in Japan By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals stock rises after partner launches YCANTH in Japan - Investing.com
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical - The Manila Times
New molluscum treatment YCANTH reaches Japanese patients after Phase 3 trial - Stock Titan
Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded to Hold Rating by Wall Street Zen - Defense World
Verrica Pharmaceuticals appoints Rosenberg as CMO - MSN
ETF Watch: Can Verrica Pharmaceuticals Inc continue delivering strong returnsWeekly Trading Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Verrica Pharmaceuticals (VRCA) upgraded to strong buy: Here's why - MSN
Verrica Pharmaceuticals (VRCA) Upgraded to Strong Buy: Here's Why - sharewise.com
Institution Moves: What hedge funds are buying Verrica Pharmaceuticals IncTrade Exit Summary & Reliable Price Action Trade Plans - baoquankhu1.vn
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Rally Mode: What is the PEG ratio of Intellicheck Inc2025 Fundamental Recap & Smart Allocation Stock Reports - baoquankhu1.vn
Sovran Advisors LLC Trims Holdings in Verrica Pharmaceuticals Inc. $VRCA - MarketBeat
Investor Alert: Common Warts Market Set for Rapid Growth – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Barchart.com
Portfolio Recap: How does KeyCorp perform in inflationary periodsEarnings Trend Report & AI Powered Market Trend Analysis - baoquankhu1.vn
Verrica doses first patient in phase 3 wart trial, eyes major label expansion - MSN
YCANTH Phase 3 Wart Study Puts Verrica in Focus While Veeva Extends Its Clinical Footprint - TipRanks
Verrica’s VP-102 Advances Dermatology Care: First Patient Dosed in Global Phase 3 Common Warts Program - Barchart.com
Aug PreEarnings: Is Verrica Pharmaceuticals Inc stock a value trapMarket Risk Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update - MarketBeat
Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded to “Buy” at Wall Street Zen - Defense World
Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Market Fear: Is Verrica Pharmaceuticals Inc stock a value trapAnalyst Downgrade & Daily Chart Pattern Signals - baoquankhu1.vn
Trade Report: Is Verrica Pharmaceuticals Inc stock good for income investorsPortfolio Gains Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences - MSN
Volume Recap: What is Life Time Group Holdings Incs P E ratio telling usJuly 2025 Gainers & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
How Much Upside is Left in Verrica Pharmaceuticals (VRCA)? Wall Street Analysts Think 97.11% - sharewise.com
Verrica Pharmaceuticals Reports Q4 2024 Growth and Pipeline Progress - MSN
Verrica Pharmaceuticals Appoints Dr. Noah Rosenberg as Chief Medical Officer - MSN
Will Verrica Pharmaceuticals Inc. stock see insider buyingTrade Analysis Report & High Win Rate Trade Alerts - ulpravda.ru
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $17.00 Consensus Target Price from Brokerages - Defense World
Verrica Doses First Patient in Phase 3 Wart Trial, Eyes Major Label Expansion - MyChesCo
Why Verrica Pharmaceuticals Inc. stock is favored by top institutionsJuly 2025 Snapshot & Free Safe Entry Trade Signal Reports - ulpravda.ru
Will Verrica Pharmaceuticals Inc. stock benefit from green energy trendsRisk Management & Free Daily Entry Point Trade Alerts - ulpravda.ru
Will Verrica Pharmaceuticals Inc. (1NE) stock outperform benchmarks2025 Major Catalysts & Accurate Trade Setup Notifications - Улправда
Verrica doses first patient in phase 3 trial for common wart treatment - Investing.com Nigeria
First Patient Dosed in Phase 3 VP-102 Common Warts Program - Dermatology Times
Verrica Pharmaceuticals stock advances as TD Cowen reiterates Buy rating By Investing.com - Investing.com Nigeria
Verrica Pharmaceuticals stock advances as TD Cowen reiterates Buy rating - Investing.com
Verrica Pharmaceuticals announces first patient dosed in phase 3 program - MarketScreener
Verrica Pharmaceuticals (VRCA) Begins Phase 3 Trials for Common Warts Treatment - GuruFocus
Verrica doses first patient in phase 3 trial for common wart treatment By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts - GlobeNewswire
Verrica Pharmaceuticals Inc (VRCA) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):